Price T Rowe Associates Inc Lucid Diagnostics Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 35,136 shares of LUCD stock, worth $36,541. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,136Holding current value
$36,541% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding LUCD
# of Institutions
70Shares Held
15.2MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA4.13MShares$4.29 Million0.0% of portfolio
-
Masters Capital Management LLC Atlanta, GA2.73MShares$2.84 Million0.13% of portfolio
-
Geode Capital Management, LLC Boston, MA1.58MShares$1.64 Million0.0% of portfolio
-
Luminus Management LLC Houston, TX913KShares$949,3170.86% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL738KShares$767,8080.0% of portfolio
About Lucid Diagnostics Inc.
- Ticker LUCD
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 38,568,500
- Market Cap $40.1M
- Description
- Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...